Contact this trialFirst, we need to learn more about you.
STAT3 Inhibitor
Oral STAT3 Inhibitor for Cancer
Recruiting1 awardPhase 1
Atlanta, Georgia
This trial will test a new compound, TTI-101, which is a direct inhibitor of the protein STAT3. This protein is involved in the development and growth of many types of cancer, but there is no current drug that targets it. TTI-101 will be given orally to patients with various types of solid tumors, to determine if it is safe and effective in reducing the growth of these tumors.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.